GlassScriptPhysician profile
Erika Daoust
NPI 1578002416
$854.34
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $476 · 2022: $310 · 2023: $68.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $68.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $68.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $226.62 | 2021-2022 | |
| Scynexis, INC. | $148.81 | 2021 | |
| Janssen Pharmaceuticals, INC | $124.60 | 2021 | |
| Alexion Pharmaceuticals, INC. | $107.10 | 2022 | |
| Cequr Corporation | $95.85 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $83.20 | 2021 | |
| Boston Scientific Corporation | $68.16 | 2023 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Daoust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.